No Data
No Data
kpc pharmaceuticals, inc. Semi-Annual Report for 2024
Summary of kpc pharmaceuticals, inc.'s 2024 interim report
KPC Pharmaceuticals, Inc. (600422.SH): The net income in the first half of the year was 0.229 billion yuan, a year-on-year increase of 2.74%.
KPC Pharmaceuticals, Inc. (600422.SH) released its semi-annual report on August 22, 2024. In the first half of 2024, the company achieved revenue of 3.55 billion yuan. Due to the continuous optimization of the business structure and the impact of related policies on the injection business, the revenue decreased by 5.73% compared to the same period last year. The company continued to improve efficiency and achieved a net income of 0.229 billion yuan attributable to shareholders of the listed company, an increase of 2.74% compared to the same period last year; the net cash flow from operating activities was 135.2018 million yuan, an increase of 146.75% compared to the same period last year. 2024 is the year when the company joined the China Resources family.
Pulling Back 4.7% This Week, KPC PharmaceuticalsInc's SHSE:600422) Three-year Decline in Earnings May Be Coming Into Investors Focus
KPC Pharmaceuticals, Inc. (600422.SH): Antibiotics such as ciprofloxacin hydrochloride tablets can be used to treat anthrax.
Kpc Pharmaceuticals, Inc. (600422.SH) stated on the investor interaction platform on August 14 that the company currently has antibiotics such as minocycline hydrochloride capsules, amoxicillin capsules, and ciprofloxacin hydrochloride tablets available for the treatment of anthrax.
kpc pharmaceuticals, inc. (600422.SH): No plans to participate in the Olympic Games at present.
kpc pharmaceuticals, inc. (600422.SH) stated on the investor interaction platform on August 6th that the company currently has no plans to participate in the Olympics.
No Data